Skip to content
OpenCapital
Get started

Zymeworks ZYME Trading assets

Trading assets at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$66.81M-64.8%
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
——

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.79B+125%

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's trading assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's trading assets?
Zymeworks (ZYME) reported trading assets of $120.45M in Q1 2026.
How has Zymeworks's trading assets changed year-over-year?
Zymeworks's trading assets decreased by 36.3% year-over-year, from $189.08M to $120.45M.
What is the long-term trend for Zymeworks's trading assets?
Over 2 years (2023 to 2025), Zymeworks's trading assets has grown at a -7.0% compound annual growth rate (CAGR), from $216.77M to $187.64M.
What does trading assets mean?
Securities and other financial instruments held for short-term trading purposes, measured at fair value with changes flowing through the income statement.